top of page

Cardiovascular

Health

CardioMetabolic 

Health

Lung Health

Bone Health

All-in-one AI-CVD

497e6f54-782b-4e077a-3a7144e4f3e4.png

AutoFracture

(coming soon)

upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
0bdba309-a76a-4215-b207-90a7932bb681.png
iScreen Shoter - 20260520111737117 1.png
Frame 1000004271.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520100645073 1.png

1 Non-Contrast Scan              10+ Actionable Reports

What if a CAC score of zero isn’t truly zero?

  • Aug 17
  • 1 min read

Updated: Aug 28


ESC 2026 · 10 Scientific Presentations · Oral & Poster · 4/10

 

HeartLung's AI-CAC can detect small and semi-calcified plaques invisible to human eyes.Same scan. A more refined “zero.”


Organised by: European Society of Cardiology (ESC) visual




For decades, a coronary artery calcium (CAC) score of zero has been one of the most reassuring findings in cardiovascular prevention.

 

However, a small portion of individuals with CAC=0 experience an adverse coronary cardiovascular event.    

 

At ESC Congress 2026, HeartLung.AI presented Agatston-2.0 - a next-generation AI-based approach designed to detect clinically meaningful coronary calcification that may be missed by conventional Agatston scoring.


Roughly 1 in 5 “zeros” was not actually zero.

 

Among 3,965 participants from MESA and the Framingham Heart Study - all with a conventional Agatston score of zero:

 

21.7% had detectable AI-CAC with Agatston-2.0.

Those with AI-CAC > 0 had:

  • 73% higher adjusted risk of myocardial infarction

  • 85% higher risk of hard CHD

  • 71% higher risk of all CHD

  • Greater progression to conventional CAC > 0 at 10 years: 66.3% vs. 43.4%



    Agatston-2.0 · See What Conventional CAC Scoring May Miss

     

    Agatston-2.0 uses deep-learning coronary segmentation, intensity calibration, continuous voxel-level weighting, and spatial filtering - all from the same non-contrast CT scan.

     


Same scan. No extra radiation. A more precise understanding of cardiovascular risk.

Download the full ESC Congress 2026 presentation to explore the Agatston-2.0 methodology, clinical outcomes, subgroup analyses, and future directions.




Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page